NIPH Clinical Trials Search

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

Basic Information

Recruitment status	Recruiting
Health condition(s) or Problem(s) studied	Hypertension
Date of first enrollment	26/06/2025
Target sample size	974
Countries of recruitment	United States,Japan,Argentina,Japan,China,Japan,Czechia,Japan,Germany,Japan,Greece,Japan,India,Japan,Poland,Japan,Puerto Rico,Japan,Spain,Japan
Study type	Interventional
Intervention(s)	DRUG: Orforglipron(Other Name: LY3502970) Administered orally. DRUG: Placebo Administered orally. (Study Arms) Experimental: Orforglipron (GZL1) Participants will receive orforglipron orally or placebo. Interventions: Drug: Orforglipron Drug: Placebo Experimental: Orforglipron (GZL2) Participants will receive orforglipron orally or placebo. Interventions: Drug: Orforglipron Drug: Placebo

Outcome(s)

Primary Outcome	Number of Participants Allocated to Each ISA [ Time Frame: Week -8 to Week 0
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	>= 18age old
Age maximum	Not applicable
Gender	Both
Include criteria	- Has systolic blood pressure (SBP) >= 140 mmHg and/or diastolic blood pressure (DBP) >= 90 mmHg (if DBP criteria alone is met, SBP must be >=130 mmHg) at screening (Visit 1). - Has SBP >= 140 mmHg and/or DBP >= 90 mmHg (if DBP criteria alone is met, SBP must be >=130 mmHg) at week 0 (Visit 3). - Untreated for hypertension, or on stable antihypertensive medications >= 30 days prior to Visit 1. - Have a body mass index (BMI) >= 25 kg/m2.
Exclude criteria	- Has SBP >=170 mmHg and/or DBP >=110 mmHg at Visit 1 or at Visit 3. - Has known secondary causes of hypertension - Have heart failure with reduced ejection fraction (HFrEF) diagnosis - Have had any of the following conditions within 90 days prior to screening. * hospitalization for hypertension or for congestive heart failure * acute coronary syndrome or acute myocardial infarction, or * cerebrovascular accident (stroke). - Have type 1 diabetes (T1D) - Have acute or chronic hepatitis, including a history of autoimmune hepatitis